nodes	percent_of_prediction	percent_of_DWPC	metapath
Diflunisal—PTGS2—thyroid cancer	0.725	1	CbGaD
Diflunisal—ALB—Vandetanib—thyroid cancer	0.0367	1	CbGbCtD
Diflunisal—Gastrointestinal perforation—Sorafenib—thyroid cancer	0.00883	0.0538	CcSEcCtD
Diflunisal—Allergic cutaneous angiitis—Sorafenib—thyroid cancer	0.00725	0.0441	CcSEcCtD
Diflunisal—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00603	0.0925	CbGpPWpGaD
Diflunisal—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00478	0.0734	CbGpPWpGaD
Diflunisal—Nephrotic syndrome—Sorafenib—thyroid cancer	0.00477	0.029	CcSEcCtD
Diflunisal—Leukocytoclastic vasculitis—Sorafenib—thyroid cancer	0.0047	0.0286	CcSEcCtD
Diflunisal—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00453	0.0695	CbGpPWpGaD
Diflunisal—Tubulointerstitial nephritis—Vandetanib—thyroid cancer	0.00446	0.0272	CcSEcCtD
Diflunisal—TTR—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00436	0.067	CbGpPWpGaD
Diflunisal—Proteinuria—Vandetanib—thyroid cancer	0.00389	0.0237	CcSEcCtD
Diflunisal—Protein urine present—Vandetanib—thyroid cancer	0.00383	0.0234	CcSEcCtD
Diflunisal—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.0036	0.0552	CbGpPWpGaD
Diflunisal—TTR—Non-integrin membrane-ECM interactions—LAMA2—thyroid cancer	0.00352	0.054	CbGpPWpGaD
Diflunisal—Tubulointerstitial nephritis—Sorafenib—thyroid cancer	0.00301	0.0183	CcSEcCtD
Diflunisal—Proteinuria—Sorafenib—thyroid cancer	0.00262	0.016	CcSEcCtD
Diflunisal—Protein urine present—Sorafenib—thyroid cancer	0.00259	0.0158	CcSEcCtD
Diflunisal—Olsalazine—PPARG—thyroid cancer	0.00253	0.275	CrCbGaD
Diflunisal—Gastrointestinal haemorrhage—Vandetanib—thyroid cancer	0.00248	0.0151	CcSEcCtD
Diflunisal—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00246	0.0378	CbGpPWpGaD
Diflunisal—Gastritis—Vandetanib—thyroid cancer	0.00219	0.0134	CcSEcCtD
Diflunisal—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00214	0.0329	CbGpPWpGaD
Diflunisal—Bronchospasm—Vandetanib—thyroid cancer	0.00211	0.0128	CcSEcCtD
Diflunisal—Dysuria—Vandetanib—thyroid cancer	0.002	0.0122	CcSEcCtD
Diflunisal—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00196	0.0119	CcSEcCtD
Diflunisal—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00195	0.03	CbGpPWpGaD
Diflunisal—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00189	0.0115	CcSEcCtD
Diflunisal—Renal failure—Vandetanib—thyroid cancer	0.00188	0.0114	CcSEcCtD
Diflunisal—Mesalazine—PPARG—thyroid cancer	0.00187	0.203	CrCbGaD
Diflunisal—Stomatitis—Vandetanib—thyroid cancer	0.00186	0.0113	CcSEcCtD
Diflunisal—Haematuria—Vandetanib—thyroid cancer	0.00182	0.0111	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Sorafenib—thyroid cancer	0.00177	0.0108	CcSEcCtD
Diflunisal—Visual impairment—Vandetanib—thyroid cancer	0.00165	0.0101	CcSEcCtD
Diflunisal—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00164	0.0251	CbGpPWpGaD
Diflunisal—Erythema multiforme—Vandetanib—thyroid cancer	0.00162	0.00988	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00151	0.00917	CcSEcCtD
Diflunisal—Gastritis—Sorafenib—thyroid cancer	0.00148	0.00902	CcSEcCtD
Diflunisal—Muscle spasms—Vandetanib—thyroid cancer	0.00144	0.00874	CcSEcCtD
Diflunisal—Vision blurred—Vandetanib—thyroid cancer	0.00141	0.00857	CcSEcCtD
Diflunisal—Loss of consciousness—Vandetanib—thyroid cancer	0.00131	0.00799	CcSEcCtD
Diflunisal—TTR—Amyloids—CALCA—thyroid cancer	0.0013	0.02	CbGpPWpGaD
Diflunisal—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0013	0.0199	CbGpPWpGaD
Diflunisal—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00128	0.00778	CcSEcCtD
Diflunisal—Chest pain—Vandetanib—thyroid cancer	0.00127	0.00774	CcSEcCtD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00127	0.0195	CbGpPWpGaD
Diflunisal—Renal failure—Sorafenib—thyroid cancer	0.00127	0.00772	CcSEcCtD
Diflunisal—Jaundice—Sorafenib—thyroid cancer	0.00126	0.00765	CcSEcCtD
Diflunisal—Stomatitis—Sorafenib—thyroid cancer	0.00126	0.00765	CcSEcCtD
Diflunisal—Oedema—Vandetanib—thyroid cancer	0.00122	0.00742	CcSEcCtD
Diflunisal—Thrombocytopenia—Vandetanib—thyroid cancer	0.00119	0.00727	CcSEcCtD
Diflunisal—Insomnia—Vandetanib—thyroid cancer	0.0011	0.00671	CcSEcCtD
Diflunisal—Paraesthesia—Vandetanib—thyroid cancer	0.00109	0.00667	CcSEcCtD
Diflunisal—Erythema multiforme—Sorafenib—thyroid cancer	0.00109	0.00666	CcSEcCtD
Diflunisal—Dyspnoea—Vandetanib—thyroid cancer	0.00109	0.00662	CcSEcCtD
Diflunisal—Tinnitus—Sorafenib—thyroid cancer	0.00108	0.00657	CcSEcCtD
Diflunisal—Flushing—Sorafenib—thyroid cancer	0.00107	0.00654	CcSEcCtD
Diflunisal—Dyspepsia—Vandetanib—thyroid cancer	0.00107	0.00653	CcSEcCtD
Diflunisal—Olsalazine—PTGS2—thyroid cancer	0.00107	0.116	CrCbGaD
Diflunisal—Decreased appetite—Vandetanib—thyroid cancer	0.00106	0.00645	CcSEcCtD
Diflunisal—Fatigue—Vandetanib—thyroid cancer	0.00105	0.0064	CcSEcCtD
Diflunisal—Constipation—Vandetanib—thyroid cancer	0.00104	0.00635	CcSEcCtD
Diflunisal—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.00104	0.0159	CbGpPWpGaD
Diflunisal—Aminosalicylic Acid—PTGS2—thyroid cancer	0.001	0.109	CrCbGaD
Diflunisal—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000997	0.00607	CcSEcCtD
Diflunisal—Muscle spasms—Sorafenib—thyroid cancer	0.000969	0.0059	CcSEcCtD
Diflunisal—Body temperature increased—Vandetanib—thyroid cancer	0.000964	0.00587	CcSEcCtD
Diflunisal—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000944	0.0145	CbGpPWpGaD
Diflunisal—Angioedema—Sorafenib—thyroid cancer	0.000921	0.00561	CcSEcCtD
Diflunisal—Salsalate—PTGS2—thyroid cancer	0.000909	0.0986	CrCbGaD
Diflunisal—Syncope—Sorafenib—thyroid cancer	0.000904	0.0055	CcSEcCtD
Diflunisal—Loss of consciousness—Sorafenib—thyroid cancer	0.000886	0.00539	CcSEcCtD
Diflunisal—Asthenia—Vandetanib—thyroid cancer	0.000875	0.00533	CcSEcCtD
Diflunisal—Pruritus—Vandetanib—thyroid cancer	0.000862	0.00525	CcSEcCtD
Diflunisal—Eructation—Epirubicin—thyroid cancer	0.000837	0.0051	CcSEcCtD
Diflunisal—Diarrhoea—Vandetanib—thyroid cancer	0.000834	0.00508	CcSEcCtD
Diflunisal—UGT1A8—Biological oxidations—RXRA—thyroid cancer	0.000834	0.0128	CbGpPWpGaD
Diflunisal—Anaphylactic shock—Sorafenib—thyroid cancer	0.000822	0.00501	CcSEcCtD
Diflunisal—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000813	0.0125	CbGpPWpGaD
Diflunisal—TTR—Extracellular matrix organization—LAMA2—thyroid cancer	0.000809	0.0124	CbGpPWpGaD
Diflunisal—Shock—Sorafenib—thyroid cancer	0.000809	0.00493	CcSEcCtD
Diflunisal—Dizziness—Vandetanib—thyroid cancer	0.000806	0.00491	CcSEcCtD
Diflunisal—Thrombocytopenia—Sorafenib—thyroid cancer	0.000805	0.0049	CcSEcCtD
Diflunisal—Mesalazine—PTGS2—thyroid cancer	0.000788	0.0855	CrCbGaD
Diflunisal—Anorexia—Sorafenib—thyroid cancer	0.000784	0.00477	CcSEcCtD
Diflunisal—Vomiting—Vandetanib—thyroid cancer	0.000775	0.00472	CcSEcCtD
Diflunisal—Eructation—Doxorubicin—thyroid cancer	0.000774	0.00472	CcSEcCtD
Diflunisal—Rash—Vandetanib—thyroid cancer	0.000769	0.00468	CcSEcCtD
Diflunisal—Dermatitis—Vandetanib—thyroid cancer	0.000768	0.00468	CcSEcCtD
Diflunisal—Headache—Vandetanib—thyroid cancer	0.000764	0.00465	CcSEcCtD
Diflunisal—Dyspnoea—Sorafenib—thyroid cancer	0.000733	0.00446	CcSEcCtD
Diflunisal—Nausea—Vandetanib—thyroid cancer	0.000724	0.00441	CcSEcCtD
Diflunisal—Dyspepsia—Sorafenib—thyroid cancer	0.000724	0.00441	CcSEcCtD
Diflunisal—Decreased appetite—Sorafenib—thyroid cancer	0.000715	0.00435	CcSEcCtD
Diflunisal—Fatigue—Sorafenib—thyroid cancer	0.000709	0.00432	CcSEcCtD
Diflunisal—Photosensitivity—Epirubicin—thyroid cancer	0.000704	0.00429	CcSEcCtD
Diflunisal—Constipation—Sorafenib—thyroid cancer	0.000703	0.00428	CcSEcCtD
Diflunisal—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.000683	0.0105	CbGpPWpGaD
Diflunisal—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000672	0.00409	CcSEcCtD
Diflunisal—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000655	0.00399	CcSEcCtD
Diflunisal—Urticaria—Sorafenib—thyroid cancer	0.000653	0.00398	CcSEcCtD
Diflunisal—Photosensitivity—Doxorubicin—thyroid cancer	0.000652	0.00397	CcSEcCtD
Diflunisal—Body temperature increased—Sorafenib—thyroid cancer	0.00065	0.00396	CcSEcCtD
Diflunisal—Renal impairment—Epirubicin—thyroid cancer	0.00065	0.00396	CcSEcCtD
Diflunisal—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000636	0.00977	CbGpPWpGaD
Diflunisal—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000618	0.00377	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—MINPP1—thyroid cancer	0.000613	0.0094	CbGpPWpGaD
Diflunisal—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000606	0.00369	CcSEcCtD
Diflunisal—Hypersensitivity—Sorafenib—thyroid cancer	0.000606	0.00369	CcSEcCtD
Diflunisal—Renal impairment—Doxorubicin—thyroid cancer	0.000601	0.00366	CcSEcCtD
Diflunisal—Asthenia—Sorafenib—thyroid cancer	0.00059	0.00359	CcSEcCtD
Diflunisal—Pruritus—Sorafenib—thyroid cancer	0.000582	0.00354	CcSEcCtD
Diflunisal—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000572	0.00348	CcSEcCtD
Diflunisal—Diarrhoea—Sorafenib—thyroid cancer	0.000563	0.00343	CcSEcCtD
Diflunisal—Salicylic acid—PTGS2—thyroid cancer	0.000559	0.0606	CrCbGaD
Diflunisal—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000557	0.00339	CcSEcCtD
Diflunisal—Gastritis—Epirubicin—thyroid cancer	0.000547	0.00333	CcSEcCtD
Diflunisal—Dizziness—Sorafenib—thyroid cancer	0.000544	0.00331	CcSEcCtD
Diflunisal—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000528	0.0081	CbGpPWpGaD
Diflunisal—Vomiting—Sorafenib—thyroid cancer	0.000523	0.00318	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—NDUFA13—thyroid cancer	0.000521	0.00799	CbGpPWpGaD
Diflunisal—Rash—Sorafenib—thyroid cancer	0.000518	0.00316	CcSEcCtD
Diflunisal—Dermatitis—Sorafenib—thyroid cancer	0.000518	0.00315	CcSEcCtD
Diflunisal—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000515	0.00314	CcSEcCtD
Diflunisal—Headache—Sorafenib—thyroid cancer	0.000515	0.00314	CcSEcCtD
Diflunisal—Gastritis—Doxorubicin—thyroid cancer	0.000506	0.00308	CcSEcCtD
Diflunisal—Dysuria—Epirubicin—thyroid cancer	0.0005	0.00304	CcSEcCtD
Diflunisal—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000494	0.00757	CbGpPWpGaD
Diflunisal—Flurbiprofen—PTGS2—thyroid cancer	0.00049	0.0531	CrCbGaD
Diflunisal—UGT1A8—Metabolism—CHST14—thyroid cancer	0.00049	0.00752	CbGpPWpGaD
Diflunisal—Nausea—Sorafenib—thyroid cancer	0.000488	0.00297	CcSEcCtD
Diflunisal—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000488	0.00297	CcSEcCtD
Diflunisal—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000472	0.00288	CcSEcCtD
Diflunisal—Renal failure—Epirubicin—thyroid cancer	0.000468	0.00285	CcSEcCtD
Diflunisal—Stomatitis—Epirubicin—thyroid cancer	0.000464	0.00283	CcSEcCtD
Diflunisal—Jaundice—Epirubicin—thyroid cancer	0.000464	0.00283	CcSEcCtD
Diflunisal—Dysuria—Doxorubicin—thyroid cancer	0.000462	0.00282	CcSEcCtD
Diflunisal—Sweating—Epirubicin—thyroid cancer	0.000457	0.00278	CcSEcCtD
Diflunisal—Haematuria—Epirubicin—thyroid cancer	0.000454	0.00277	CcSEcCtD
Diflunisal—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000451	0.00275	CcSEcCtD
Diflunisal—Agranulocytosis—Epirubicin—thyroid cancer	0.000445	0.00271	CcSEcCtD
Diflunisal—TTR—Disease—TRIM24—thyroid cancer	0.000443	0.0068	CbGpPWpGaD
Diflunisal—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000442	0.00678	CbGpPWpGaD
Diflunisal—TTR—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000441	0.00677	CbGpPWpGaD
Diflunisal—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000437	0.00266	CcSEcCtD
Diflunisal—Renal failure—Doxorubicin—thyroid cancer	0.000433	0.00264	CcSEcCtD
Diflunisal—Stomatitis—Doxorubicin—thyroid cancer	0.00043	0.00262	CcSEcCtD
Diflunisal—Jaundice—Doxorubicin—thyroid cancer	0.00043	0.00262	CcSEcCtD
Diflunisal—Hepatitis—Epirubicin—thyroid cancer	0.000428	0.0026	CcSEcCtD
Diflunisal—Sweating—Doxorubicin—thyroid cancer	0.000423	0.00257	CcSEcCtD
Diflunisal—Haematuria—Doxorubicin—thyroid cancer	0.00042	0.00256	CcSEcCtD
Diflunisal—TTR—Disease—CHST14—thyroid cancer	0.000417	0.00639	CbGpPWpGaD
Diflunisal—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000414	0.00635	CbGpPWpGaD
Diflunisal—Visual impairment—Epirubicin—thyroid cancer	0.000412	0.00251	CcSEcCtD
Diflunisal—Agranulocytosis—Doxorubicin—thyroid cancer	0.000411	0.00251	CcSEcCtD
Diflunisal—Erythema multiforme—Epirubicin—thyroid cancer	0.000404	0.00246	CcSEcCtD
Diflunisal—Tinnitus—Epirubicin—thyroid cancer	0.000399	0.00243	CcSEcCtD
Diflunisal—Flushing—Epirubicin—thyroid cancer	0.000397	0.00242	CcSEcCtD
Diflunisal—Hepatitis—Doxorubicin—thyroid cancer	0.000396	0.00241	CcSEcCtD
Diflunisal—TTR—Disease—TRIM33—thyroid cancer	0.000395	0.00606	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—HPGD—thyroid cancer	0.000395	0.00606	CbGpPWpGaD
Diflunisal—Visual impairment—Doxorubicin—thyroid cancer	0.000381	0.00232	CcSEcCtD
Diflunisal—Erythema multiforme—Doxorubicin—thyroid cancer	0.000374	0.00228	CcSEcCtD
Diflunisal—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000372	0.00571	CbGpPWpGaD
Diflunisal—Tinnitus—Doxorubicin—thyroid cancer	0.000369	0.00225	CcSEcCtD
Diflunisal—Flushing—Doxorubicin—thyroid cancer	0.000367	0.00224	CcSEcCtD
Diflunisal—Flatulence—Epirubicin—thyroid cancer	0.000367	0.00223	CcSEcCtD
Diflunisal—Tension—Epirubicin—thyroid cancer	0.000365	0.00223	CcSEcCtD
Diflunisal—Nervousness—Epirubicin—thyroid cancer	0.000362	0.0022	CcSEcCtD
Diflunisal—Muscle spasms—Epirubicin—thyroid cancer	0.000358	0.00218	CcSEcCtD
Diflunisal—Vision blurred—Epirubicin—thyroid cancer	0.000351	0.00214	CcSEcCtD
Diflunisal—Flatulence—Doxorubicin—thyroid cancer	0.00034	0.00207	CcSEcCtD
Diflunisal—Tension—Doxorubicin—thyroid cancer	0.000338	0.00206	CcSEcCtD
Diflunisal—Nervousness—Doxorubicin—thyroid cancer	0.000335	0.00204	CcSEcCtD
Diflunisal—Vertigo—Epirubicin—thyroid cancer	0.000335	0.00204	CcSEcCtD
Diflunisal—Syncope—Epirubicin—thyroid cancer	0.000334	0.00203	CcSEcCtD
Diflunisal—Muscle spasms—Doxorubicin—thyroid cancer	0.000331	0.00202	CcSEcCtD
Diflunisal—Palpitations—Epirubicin—thyroid cancer	0.000329	0.002	CcSEcCtD
Diflunisal—Loss of consciousness—Epirubicin—thyroid cancer	0.000327	0.00199	CcSEcCtD
Diflunisal—Vision blurred—Doxorubicin—thyroid cancer	0.000325	0.00198	CcSEcCtD
Diflunisal—Chest pain—Epirubicin—thyroid cancer	0.000317	0.00193	CcSEcCtD
Diflunisal—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00031	0.00476	CbGpPWpGaD
Diflunisal—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00031	0.00476	CbGpPWpGaD
Diflunisal—Vertigo—Doxorubicin—thyroid cancer	0.00031	0.00188	CcSEcCtD
Diflunisal—Syncope—Doxorubicin—thyroid cancer	0.000309	0.00188	CcSEcCtD
Diflunisal—Confusional state—Epirubicin—thyroid cancer	0.000306	0.00187	CcSEcCtD
Diflunisal—Palpitations—Doxorubicin—thyroid cancer	0.000304	0.00185	CcSEcCtD
Diflunisal—Anaphylactic shock—Epirubicin—thyroid cancer	0.000304	0.00185	CcSEcCtD
Diflunisal—Oedema—Epirubicin—thyroid cancer	0.000304	0.00185	CcSEcCtD
Diflunisal—Loss of consciousness—Doxorubicin—thyroid cancer	0.000303	0.00184	CcSEcCtD
Diflunisal—Shock—Epirubicin—thyroid cancer	0.000299	0.00182	CcSEcCtD
Diflunisal—Thrombocytopenia—Epirubicin—thyroid cancer	0.000298	0.00181	CcSEcCtD
Diflunisal—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000296	0.00454	CbGpPWpGaD
Diflunisal—Hyperhidrosis—Epirubicin—thyroid cancer	0.000294	0.00179	CcSEcCtD
Diflunisal—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000293	0.0045	CbGpPWpGaD
Diflunisal—Chest pain—Doxorubicin—thyroid cancer	0.000293	0.00179	CcSEcCtD
Diflunisal—TTR—Signaling Pathways—CALCB—thyroid cancer	0.000292	0.00448	CbGpPWpGaD
Diflunisal—Anorexia—Epirubicin—thyroid cancer	0.00029	0.00176	CcSEcCtD
Diflunisal—Confusional state—Doxorubicin—thyroid cancer	0.000284	0.00173	CcSEcCtD
Diflunisal—Oedema—Doxorubicin—thyroid cancer	0.000281	0.00171	CcSEcCtD
Diflunisal—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000281	0.00171	CcSEcCtD
Diflunisal—Shock—Doxorubicin—thyroid cancer	0.000277	0.00168	CcSEcCtD
Diflunisal—TTR—Signaling Pathways—TRIM33—thyroid cancer	0.000277	0.00424	CbGpPWpGaD
Diflunisal—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000275	0.00168	CcSEcCtD
Diflunisal—Insomnia—Epirubicin—thyroid cancer	0.000275	0.00167	CcSEcCtD
Diflunisal—Paraesthesia—Epirubicin—thyroid cancer	0.000273	0.00166	CcSEcCtD
Diflunisal—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000272	0.00166	CcSEcCtD
Diflunisal—Dyspnoea—Epirubicin—thyroid cancer	0.000271	0.00165	CcSEcCtD
Diflunisal—Somnolence—Epirubicin—thyroid cancer	0.00027	0.00165	CcSEcCtD
Diflunisal—Anorexia—Doxorubicin—thyroid cancer	0.000268	0.00163	CcSEcCtD
Diflunisal—Dyspepsia—Epirubicin—thyroid cancer	0.000268	0.00163	CcSEcCtD
Diflunisal—Decreased appetite—Epirubicin—thyroid cancer	0.000264	0.00161	CcSEcCtD
Diflunisal—TTR—Disease—TCF7L1—thyroid cancer	0.000264	0.00404	CbGpPWpGaD
Diflunisal—Fatigue—Epirubicin—thyroid cancer	0.000262	0.0016	CcSEcCtD
Diflunisal—Constipation—Epirubicin—thyroid cancer	0.00026	0.00158	CcSEcCtD
Diflunisal—Insomnia—Doxorubicin—thyroid cancer	0.000254	0.00155	CcSEcCtD
Diflunisal—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000254	0.0039	CbGpPWpGaD
Diflunisal—Paraesthesia—Doxorubicin—thyroid cancer	0.000252	0.00154	CcSEcCtD
Diflunisal—Dyspnoea—Doxorubicin—thyroid cancer	0.000251	0.00153	CcSEcCtD
Diflunisal—Feeling abnormal—Epirubicin—thyroid cancer	0.00025	0.00152	CcSEcCtD
Diflunisal—Somnolence—Doxorubicin—thyroid cancer	0.00025	0.00152	CcSEcCtD
Diflunisal—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000249	0.00151	CcSEcCtD
Diflunisal—Dyspepsia—Doxorubicin—thyroid cancer	0.000248	0.00151	CcSEcCtD
Diflunisal—Decreased appetite—Doxorubicin—thyroid cancer	0.000244	0.00149	CcSEcCtD
Diflunisal—Fatigue—Doxorubicin—thyroid cancer	0.000242	0.00148	CcSEcCtD
Diflunisal—Urticaria—Epirubicin—thyroid cancer	0.000241	0.00147	CcSEcCtD
Diflunisal—Constipation—Doxorubicin—thyroid cancer	0.00024	0.00146	CcSEcCtD
Diflunisal—Body temperature increased—Epirubicin—thyroid cancer	0.00024	0.00146	CcSEcCtD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000234	0.00359	CbGpPWpGaD
Diflunisal—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000232	0.00357	CbGpPWpGaD
Diflunisal—Feeling abnormal—Doxorubicin—thyroid cancer	0.000232	0.00141	CcSEcCtD
Diflunisal—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00023	0.0014	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—TPR—thyroid cancer	0.000227	0.00348	CbGpPWpGaD
Diflunisal—Hypersensitivity—Epirubicin—thyroid cancer	0.000224	0.00136	CcSEcCtD
Diflunisal—Urticaria—Doxorubicin—thyroid cancer	0.000223	0.00136	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—PRKAR1A—thyroid cancer	0.000223	0.00342	CbGpPWpGaD
Diflunisal—Body temperature increased—Doxorubicin—thyroid cancer	0.000222	0.00135	CcSEcCtD
Diflunisal—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.00022	0.00337	CbGpPWpGaD
Diflunisal—Asthenia—Epirubicin—thyroid cancer	0.000218	0.00133	CcSEcCtD
Diflunisal—Pruritus—Epirubicin—thyroid cancer	0.000215	0.00131	CcSEcCtD
Diflunisal—Diarrhoea—Epirubicin—thyroid cancer	0.000208	0.00127	CcSEcCtD
Diflunisal—Hypersensitivity—Doxorubicin—thyroid cancer	0.000207	0.00126	CcSEcCtD
Diflunisal—Asthenia—Doxorubicin—thyroid cancer	0.000202	0.00123	CcSEcCtD
Diflunisal—Dizziness—Epirubicin—thyroid cancer	0.000201	0.00122	CcSEcCtD
Diflunisal—Pruritus—Doxorubicin—thyroid cancer	0.000199	0.00121	CcSEcCtD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000194	0.00297	CbGpPWpGaD
Diflunisal—Vomiting—Epirubicin—thyroid cancer	0.000193	0.00118	CcSEcCtD
Diflunisal—TTR—Disease—TPR—thyroid cancer	0.000193	0.00296	CbGpPWpGaD
Diflunisal—Diarrhoea—Doxorubicin—thyroid cancer	0.000192	0.00117	CcSEcCtD
Diflunisal—Rash—Epirubicin—thyroid cancer	0.000192	0.00117	CcSEcCtD
Diflunisal—Dermatitis—Epirubicin—thyroid cancer	0.000191	0.00117	CcSEcCtD
Diflunisal—Headache—Epirubicin—thyroid cancer	0.00019	0.00116	CcSEcCtD
Diflunisal—TTR—Disease—PRKAR1A—thyroid cancer	0.00019	0.00291	CbGpPWpGaD
Diflunisal—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000187	0.00287	CbGpPWpGaD
Diflunisal—Dizziness—Doxorubicin—thyroid cancer	0.000186	0.00113	CcSEcCtD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000186	0.00285	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TCF7L1—thyroid cancer	0.000185	0.00283	CbGpPWpGaD
Diflunisal—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000184	0.00283	CbGpPWpGaD
Diflunisal—TTR—Disease—MEN1—thyroid cancer	0.000181	0.00278	CbGpPWpGaD
Diflunisal—Nausea—Epirubicin—thyroid cancer	0.000181	0.0011	CcSEcCtD
Diflunisal—Vomiting—Doxorubicin—thyroid cancer	0.000179	0.00109	CcSEcCtD
Diflunisal—Rash—Doxorubicin—thyroid cancer	0.000177	0.00108	CcSEcCtD
Diflunisal—Dermatitis—Doxorubicin—thyroid cancer	0.000177	0.00108	CcSEcCtD
Diflunisal—Headache—Doxorubicin—thyroid cancer	0.000176	0.00107	CcSEcCtD
Diflunisal—UGT1A8—Metabolism—SLC5A5—thyroid cancer	0.00017	0.0026	CbGpPWpGaD
Diflunisal—Nausea—Doxorubicin—thyroid cancer	0.000167	0.00102	CcSEcCtD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000167	0.00256	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000162	0.00248	CbGpPWpGaD
Diflunisal—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000161	0.00248	CbGpPWpGaD
Diflunisal—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000161	0.00248	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000161	0.00246	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	0.000158	0.00242	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000158	0.00242	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000155	0.00238	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00015	0.0023	CbGpPWpGaD
Diflunisal—TTR—Disease—CALCA—thyroid cancer	0.000144	0.00222	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—RXRA—thyroid cancer	0.000143	0.00219	CbGpPWpGaD
Diflunisal—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000142	0.00218	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000139	0.00213	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000137	0.00211	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TSHR—thyroid cancer	0.000135	0.00207	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000133	0.00204	CbGpPWpGaD
Diflunisal—TTR—Disease—CDK1—thyroid cancer	0.000131	0.00201	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TRIM24—thyroid cancer	0.00013	0.002	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—CHST14—thyroid cancer	0.000129	0.00198	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000128	0.00197	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—MEN1—thyroid cancer	0.000127	0.00195	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CHST14—thyroid cancer	0.000122	0.00188	CbGpPWpGaD
Diflunisal—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000121	0.00185	CbGpPWpGaD
Diflunisal—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.00012	0.00184	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.00012	0.00184	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000118	0.00181	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TRIM33—thyroid cancer	0.000116	0.00178	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PTCH1—thyroid cancer	0.000115	0.00176	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000109	0.00167	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000106	0.00163	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—SST—thyroid cancer	0.000105	0.00161	CbGpPWpGaD
Diflunisal—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000105	0.00161	CbGpPWpGaD
Diflunisal—TTR—Disease—NRG1—thyroid cancer	0.000105	0.00161	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—HPGD—thyroid cancer	0.000104	0.0016	CbGpPWpGaD
Diflunisal—ALB—Metabolism—MINPP1—thyroid cancer	0.000104	0.00159	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.000103	0.00158	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—CHST14—thyroid cancer	0.000103	0.00157	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CALCA—thyroid cancer	0.000101	0.00155	CbGpPWpGaD
Diflunisal—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.92e-05	0.00152	CbGpPWpGaD
Diflunisal—TTR—Disease—TERT—thyroid cancer	9.42e-05	0.00145	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—PRKAR1A—thyroid cancer	9.32e-05	0.00143	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CDK1—thyroid cancer	9.15e-05	0.0014	CbGpPWpGaD
Diflunisal—TTR—Disease—HIF1A—thyroid cancer	9.01e-05	0.00138	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PPARG—thyroid cancer	9e-05	0.00138	CbGpPWpGaD
Diflunisal—ALB—Folate Metabolism—TP53—thyroid cancer	8.98e-05	0.00138	CbGpPWpGaD
Diflunisal—ALB—Metabolism—NDUFA13—thyroid cancer	8.82e-05	0.00135	CbGpPWpGaD
Diflunisal—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	8.76e-05	0.00134	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.45e-05	0.0013	CbGpPWpGaD
Diflunisal—ALB—Metabolism—CHST14—thyroid cancer	8.3e-05	0.00127	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—HPGD—thyroid cancer	8.27e-05	0.00127	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	8.2e-05	0.00126	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	8.2e-05	0.00126	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.07e-05	0.00124	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TCF7L1—thyroid cancer	7.74e-05	0.00119	CbGpPWpGaD
Diflunisal—TTR—Disease—BRAF—thyroid cancer	7.46e-05	0.00114	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NRG1—thyroid cancer	7.35e-05	0.00113	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	7.21e-05	0.00111	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PTGS2—thyroid cancer	7.08e-05	0.00109	CbGpPWpGaD
Diflunisal—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	6.98e-05	0.00107	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	6.95e-05	0.00107	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.7e-05	0.00103	CbGpPWpGaD
Diflunisal—ALB—Metabolism—HPGD—thyroid cancer	6.69e-05	0.00103	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TERT—thyroid cancer	6.6e-05	0.00101	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—HIF1A—thyroid cancer	6.31e-05	0.000968	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—PTEN—thyroid cancer	6.18e-05	0.000948	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—IFNA2—thyroid cancer	6.17e-05	0.000947	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.14e-05	0.000942	CbGpPWpGaD
Diflunisal—TTR—Disease—PTGS2—thyroid cancer	6.03e-05	0.000925	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—TPR—thyroid cancer	5.98e-05	0.000918	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PRKAR1A—thyroid cancer	5.88e-05	0.000903	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TPR—thyroid cancer	5.67e-05	0.00087	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PRKAR1A—thyroid cancer	5.58e-05	0.000856	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.42e-05	0.000832	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.34e-05	0.000819	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.33e-05	0.000818	CbGpPWpGaD
Diflunisal—PTGS2—Disease—MEN1—thyroid cancer	5.33e-05	0.000818	CbGpPWpGaD
Diflunisal—TTR—Disease—PTEN—thyroid cancer	5.26e-05	0.000806	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—BRAF—thyroid cancer	5.23e-05	0.000802	CbGpPWpGaD
Diflunisal—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.16e-05	0.000791	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—TPR—thyroid cancer	4.75e-05	0.000728	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.75e-05	0.000728	CbGpPWpGaD
Diflunisal—TTR—Disease—NRAS—thyroid cancer	4.69e-05	0.00072	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PRKAR1A—thyroid cancer	4.67e-05	0.000717	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—SLC5A5—thyroid cancer	4.48e-05	0.000687	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CALCA—thyroid cancer	4.24e-05	0.000651	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.23e-05	0.00065	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.19e-05	0.000644	CbGpPWpGaD
Diflunisal—TTR—Disease—KRAS—thyroid cancer	4.04e-05	0.000619	CbGpPWpGaD
Diflunisal—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.01e-05	0.000615	CbGpPWpGaD
Diflunisal—PTGS2—Disease—CDK1—thyroid cancer	3.84e-05	0.000589	CbGpPWpGaD
Diflunisal—ALB—Metabolism—TPR—thyroid cancer	3.84e-05	0.000589	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—CCND1—thyroid cancer	3.81e-05	0.000585	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PRKAR1A—thyroid cancer	3.78e-05	0.00058	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—RXRA—thyroid cancer	3.76e-05	0.000577	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—PTEN—thyroid cancer	3.68e-05	0.000565	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.66e-05	0.000561	CbGpPWpGaD
Diflunisal—UGT1A8—Metabolism—AKT1—thyroid cancer	3.56e-05	0.000546	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—SLC5A5—thyroid cancer	3.55e-05	0.000545	CbGpPWpGaD
Diflunisal—TTR—Disease—HRAS—thyroid cancer	3.43e-05	0.000526	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.42e-05	0.000525	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—NRAS—thyroid cancer	3.28e-05	0.000504	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NRG1—thyroid cancer	3.08e-05	0.000473	CbGpPWpGaD
Diflunisal—TTR—Disease—AKT1—thyroid cancer	3.03e-05	0.000465	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—RXRA—thyroid cancer	2.99e-05	0.000458	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.9e-05	0.000446	CbGpPWpGaD
Diflunisal—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	2.89e-05	0.000443	CbGpPWpGaD
Diflunisal—ALB—Metabolism—SLC5A5—thyroid cancer	2.88e-05	0.000441	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—KRAS—thyroid cancer	2.83e-05	0.000434	CbGpPWpGaD
Diflunisal—PTGS2—Disease—TERT—thyroid cancer	2.77e-05	0.000425	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.69e-05	0.000413	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HIF1A—thyroid cancer	2.65e-05	0.000406	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—TP53—thyroid cancer	2.51e-05	0.000385	CbGpPWpGaD
Diflunisal—ALB—Metabolism—RXRA—thyroid cancer	2.42e-05	0.000371	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—HRAS—thyroid cancer	2.4e-05	0.000369	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PPARG—thyroid cancer	2.37e-05	0.000364	CbGpPWpGaD
Diflunisal—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.35e-05	0.00036	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—NRAS—thyroid cancer	2.3e-05	0.000353	CbGpPWpGaD
Diflunisal—PTGS2—Disease—BRAF—thyroid cancer	2.19e-05	0.000336	CbGpPWpGaD
Diflunisal—TTR—Signaling Pathways—AKT1—thyroid cancer	2.12e-05	0.000325	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—KRAS—thyroid cancer	1.98e-05	0.000304	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PPARG—thyroid cancer	1.89e-05	0.000289	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PTGS2—thyroid cancer	1.87e-05	0.000287	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—TP53—thyroid cancer	1.76e-05	0.00027	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—HRAS—thyroid cancer	1.68e-05	0.000258	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—PTEN—thyroid cancer	1.63e-05	0.00025	CbGpPWpGaD
Diflunisal—PTGS2—Disease—PTEN—thyroid cancer	1.54e-05	0.000237	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PPARG—thyroid cancer	1.53e-05	0.000234	CbGpPWpGaD
Diflunisal—ALB—Hemostasis—AKT1—thyroid cancer	1.49e-05	0.000228	CbGpPWpGaD
Diflunisal—PTGS2—Disease—NRAS—thyroid cancer	1.38e-05	0.000211	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—PTEN—thyroid cancer	1.29e-05	0.000198	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PTGS2—thyroid cancer	1.2e-05	0.000184	CbGpPWpGaD
Diflunisal—PTGS2—Disease—KRAS—thyroid cancer	1.19e-05	0.000182	CbGpPWpGaD
Diflunisal—ALB—Metabolism—PTEN—thyroid cancer	1.05e-05	0.000161	CbGpPWpGaD
Diflunisal—PTGS2—Disease—HRAS—thyroid cancer	1.01e-05	0.000155	CbGpPWpGaD
Diflunisal—PTGS1—Metabolism—AKT1—thyroid cancer	9.39e-06	0.000144	CbGpPWpGaD
Diflunisal—PTGS2—Disease—AKT1—thyroid cancer	8.9e-06	0.000137	CbGpPWpGaD
Diflunisal—PTGS2—Metabolism—AKT1—thyroid cancer	7.45e-06	0.000114	CbGpPWpGaD
Diflunisal—ALB—Metabolism—AKT1—thyroid cancer	6.03e-06	9.25e-05	CbGpPWpGaD
